Olemedia/E+ via Getty Images Technology platform using artificial intelligence to process medical data — Tempus AI ( NASDAQ: TEM ) backed by SoftBank Group ( OTCPK:SFTBY ) priced its initial public offering of 11.1M shares at $37 per share, preparing to raise $410.7M.
The business valued itself above $6B after pricing its IPO at the higher end of its intended range of $35 to $37. Tempus AI ( TEM ) is a technology company that provides physicians to make near real-time, data-driven decisions. It aids genomics diagnostic tests in the fields of neuropsychiatry, radiology, cardiology, and oncology.
Eric Lefkofsky, the founder, CEO, and chairman, has led its management since establishment in 2015. He previously was the founder and served CEO position at Groupon. The shares are expected to begin trading on the Nasdaq on June 14, 2024, under the ticker symbol “TEM”.
The offering is expected to close on June 17, 2024. More on Tempus AI Spotlight On Apple's AI Strategy, The Fed Meeting, And Latest CPI Print Tempus AI's High Stakes IPO: A Gamble On Growth Amid Soaring Losses IPO roundup: NVL, TEM, and more Tempus, AI-based diagnostics maker, sets terms for $400M IPO Financial information for Tempus AI, Inc.